BNTX logo

BNTX
BioNTech SE - ADR

18,962
Mkt Cap
$26.51B
Volume
420,563.00
52W High
$124.00
52W Low
$81.20
PE Ratio
-41.92
BNTX Fundamentals
Price
$110.23
Prev Close
$108.80
Open
$109.00
50D MA
$105.18
Beta
0.83
Avg. Volume
1.06M
EPS (Annual)
-$2.99
P/B
1.22
Rev/Employee
$439,432.88
$10,767.80
Loading...
Loading...
News
all
press releases
BioNTech (BNTX) Expected to Announce Quarterly Earnings on Monday
BioNTech (NASDAQ:BNTX) will be releasing its Q4 2025 earnings before the market opens on Monday, March 9. (View Earnings Report at...
MarketBeat·50m ago
News Placeholder
More News
News Placeholder
Primecap Management Co. CA Sells 130,700 Shares of BioNTech SE Sponsored ADR $BNTX
Primecap Management Co. CA trimmed its holdings in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 3.3% during the 3rd quarter, according to its most recent disclosure with the...
MarketBeat·4d ago
News Placeholder
Immuno-Oncology Investments Accelerate as Pipeline Catalysts Multiply in 2026
Immuno-Oncology Investments Accelerate as Pipeline Catalysts Multiply in 2026 Immuno-Oncology Investments Accelerate as Pipeline Catalysts Multiply in 2026 PR Newswire VANCOUVER, BC, Feb. 25, 2026...
PR Newswire·5d ago
News Placeholder
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
Shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX - Get Free Report) have received an average rating of "Moderate Buy" from the sixteen research firms that are presently covering the company...
MarketBeat·10d ago
News Placeholder
BioNTech SE Sponsored ADR $BNTX Shares Sold by CenterBook Partners LP
CenterBook Partners LP trimmed its position in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 14.1% during the third quarter, according to the company in its most recent Form 13F...
MarketBeat·12d ago
News Placeholder
Aberdeen Group plc Has $28.79 Million Stock Position in BioNTech SE Sponsored ADR $BNTX
Aberdeen Group plc lowered its stake in BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 59.6% during the third quarter, according to the company in its most recent Form 13F filing with the...
MarketBeat·12d ago
News Placeholder
BMY Up 7.6% Post Q4 Earnings: Should You Buy, Sell or Hold the Stock?
BMY jumps after strong Q4 2025 results as its growth portfolio drives beats, lifts sentiment and offsets generic pressure on legacy drugs.
Zacks·21d ago
News Placeholder
Pfizer Stock Slides Despite Q4 Earnings Beat and New Obesity Drug Data
PFE shares fall even after Q4 earnings beat on COVID product declines and muted investor reaction to new obesity drug data.
Zacks·27d ago
News Placeholder
Should You Buy, Hold, or Sell BMY Stock Ahead of Q4 Earnings?
BMY heads into Q4 2025 earnings with strong Opdivo momentum, even as generic pressure continues to weigh on legacy drug sales.
Zacks·28d ago
News Placeholder
Lingohr Asset Management GmbH Acquires 40,821 Shares of BioNTech SE Sponsored ADR $BNTX
Lingohr Asset Management GmbH boosted its position in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 598.4% during the 3rd quarter, according to its most recent 13F filing with...
MarketBeat·30d ago
<
1
2
...
>

Latest BNTX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.